熱門資訊> 正文
Inozymy获得罕见钙病症候选人的快速通道状态
2024-07-03 01:43
- The U.S. FDA has granted Inozyme Pharma (NASDAQ:INZY) Fast Track designation for NZ-701, its treatment of ABCC6 Deficiency.
- The company noted it hopes to have an agreement with regulators on a pivotal trial design by the end of the year.
- In April, Inozyme released promising topline results from an ongoing phase 1/2 trial in adults showing clinical improvements were observed in vascular pathology, visual function, and patient reported outcomes.
- ABCC6 Deficiency is characterized by progressive calcification in the eyes, skin, and arteries.
More on Inozyme Pharma
- Seeking Alpha’s Quant Rating on Inozyme Pharma
- Historical earnings data for Inozyme Pharma
- Financial information for Inozyme Pharma
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
